Male Infertility: Epidemiology Report and Forecast to 2035
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Male infertility is defined by the World Health Organization (WHO) as the inability of a male to make a fertile female pregnant for a minimum of at least 1 year of regular unprotected intercourse. Approximately 15% of couples struggle with infertility. Of these couples, male factor infertility is present in an estimated 50%, and a male factor is the sole suspected etiology in approximately 20% of infertile couples (Thonneau et al., 1991). Infertility can be primary or secondary. Primary infertility is when a pregnancy has never been achieved by a person, and secondary infertility is when at least one prior pregnancy has been achieved (WHO, 2025). Oligozoospermia (or oligospermia) is a male fertility condition characterized by a low sperm concentration in the ejaculate, typically below 15 million sperm/mL (Cleveland Clinic, 2025).
In the 7MM, the number of diagnosed prevalent cases is expected to decrease by 0.63% over the forecast period at an annual growth rate (AGR) of negative 0.06%, from 3,957,575 cases in 2025 to 3,932,895 cases by 2035. In 2035, the US will have the highest number of diagnosed prevalent cases of male infertility in the 7MM with 1,923,162 cases and Spain will have the fewest diagnosed prevalent cases of male infertility with 126,085 cases. GlobalData epidemiologists attribute the slight decline in the diagnosed prevalent cases of male infertility to changes in population dynamics, as well as the diagnosed prevalence in each market.
Scope
This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for male infertility in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of male infertility. The diagnosed prevalent cases of male infertility are segmented by age (15–49 years). The model accompanying this report includes additional diagnosed prevalent cases of Oligozoospermia. This epidemiology forecast for male infertility is supported by data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed prevalent cases of male infertility across these markets.
Reasons to Buy
The Male Infertility (MI) epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global MI market.
Quantify patient populations in the global MI market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for MI therapeutics in each of the markets covered.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Male Infertility reports